Keep up with the fast pace of COVID-19 research with a series of concise “Science Spotlight” commentaries and audio podcasts featuring a pair of experts discussing the most clinically relevant new COVID-19 data.
Here are my thoughts on how developing data may help you assess immunocompromised patients’ risk of severe COVID-19 illness.
Navigating what is currently known about responsiveness to COVID-19 vaccines and the potential for SARS-CoV-2 variants in immunocompromised patients.
Neutralizing antibodies are an attractive strategy for prevention and treatment of COVID-19, particularly for unvaccinated persons and others at high risk of infection. Here’s my take on 2 exciting new studies in this field.
My take on the potential utility of casirivimab plus imdevimab for hospitalized patients with COVID-19 who have higher viral burden and delayed antibody responses.
In 2020, New York City was an epicenter of the COVID-19 pandemic, and race-related disparities in patients with COVID-19 presenting to our hospital were evident. Here’s my take on 4 new analyses showing that increased risk of COVID-19 illness and poorer outcomes reflect the preexisting, deep socioeconomic inequities that affect health and access to healthcare.
In this commentary, I review recent studies assessing the potential role for TDF in limiting SARS-CoV-2 replication.
What if one in 4 COVID-19 deaths during a surge could be avoided? My take on important new data showing that COVID-19 caseload surges adversely affect COVID-19 mortality rates.
Do we already have an FDA-approved, safe, and inexpensive drug that could benefit patients with COVID-19? Take a look at these promising studies of a repurposed drug—fluvoxamine—for COVID-19.